Peer Exchange

Experts in cardiovascular medicine share strategies for the practical management of obstructive hypertrophic cardiomyopathy.

A panel of experts discusses use of antithrombotic therapy for treatment of polyvascular disease, in particular coronary artery disease (CAD). They also share data in patients with CAD and peripheral artery disease (PAD) with dual pathway inhibition (DPI) and their insights on optimal duration of dual antiplatelet therapy (DAPT) and rationale for switching therapy.

Linda Stein Gold, MD; Raj J. Chovatiya, MD, PhD; Eric Simpson, MD, MCR; and Alexandra K. Golant, MD, share their approaches to optimizing the treatment of atopic dermatitis with a focus on the utilization of topical and oral JAK inhibitors.

Experts in endocrinology and cardiology discuss various guideline and treatments for the management of ASCVD and hypercholesterolemia.

Nada Elbuluk, MD, MSc, FAAD, explores the clinical burden of vitiligo and examines the current and future treatment landscape in this upcoming HCPLive Peer Exchange program.

Raj J. Chovatiya, MD, PhD, shares insight on optimizing treatment for patients with atopic dermatitis and addresses unmet needs in the current treatment landscape in this upcoming HCPLive Cure Connections program.

A panel of experts explore the patient journey and unmet needs of patients with treatment resistant depression (TRD), outline treatment strategies for TRD outside of oral antidepressants/antipsychotics and explore strategies to support access to these alternative therapies through improved billing/coding strategies.

Key opinion leaders explore the diagnosis, management, and treatment of attention deficit hyperactivity disorder (ADHD) in the adult population and share key insights on the evolving treatment landscape.

A panel of experts discuss the diagnosis, management, and treatment options for peripheral artery disease (PAD), as well as what can be done to improve the treatment landscape.

Expert panelists reflect on the selection and use of recently approved treatments, including interleukin pathway inhibitors, for type 2 inflammation in atopic dermatitis.